79
https://pubmed.ncbi.nlm.nih.gov/38117806
The abstract reports that transferrin receptor is highly expressed in primary and metastatic breast cancer, including after chemotherapy, and that an iron chelator can enhance its expression, suggesting potential for improved targeting of breast cancer using transferrin-conjugated agents.
